• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小鼠肺癌模型的方法学模拟了临床肺腺癌的进展和转移。

Methodology of murine lung cancer mimics clinical lung adenocarcinoma progression and metastasis.

作者信息

Kim Edison Q, Kim Emily Y, Knott Eric P, Wang Yujie, Chen Cheng-Bang, Conejo-Garcia Jose R, Wangpaichitr Medhi, Lim Diane C

机构信息

Research Services, Miami VA Healthcare System, Miami, FL, 33125, USA.

South Florida Veterans Affairs Foundation for Research and Education, Miami, FL, 33125, USA.

出版信息

Sci Rep. 2025 Feb 28;15(1):7127. doi: 10.1038/s41598-025-90344-1.

DOI:10.1038/s41598-025-90344-1
PMID:40021683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11871348/
Abstract

Lung cancer is the leading cause of cancer-related deaths, of which adenocarcinoma is the most common subtype. Despite this, lung adenocarcinoma and its metastasis are poorly understood, due to difficulties in feasibly recapitulating disease progression and predicting clinical benefits of therapy. We outline a methodology to develop immunogenic orthotopic lung adenocarcinoma mouse models, by injecting cell-specific cre viruses into the lung of a genetically engineered mouse, which mirrors cancer progression defined by the International Association for the Study of Lung Cancer. Evaluation of different cre virus/concentrations models demonstrate remarkable consistency in cancer initiation and metastasis, allowing for high throughput, while showing differences in timing and severity, offering greater flexibility when selecting models. Histological and immune profiles reflect clinical observations suggesting similar mechanisms are recapitulated and preliminary data show resultant tumors to be responsive to clinical treatments. We present a clinically relevant, next-generation murine model for studying lung adenocarcinoma.

摘要

肺癌是癌症相关死亡的主要原因,其中腺癌是最常见的亚型。尽管如此,由于难以切实重现疾病进展并预测治疗的临床益处,肺腺癌及其转移仍未得到充分了解。我们概述了一种开发免疫原性原位肺腺癌小鼠模型的方法,即通过将细胞特异性cre病毒注射到基因工程小鼠的肺部,该模型反映了国际肺癌研究协会定义的癌症进展。对不同cre病毒/浓度模型的评估表明,在癌症起始和转移方面具有显著的一致性,可实现高通量,同时在时间和严重程度上存在差异,在选择模型时提供了更大的灵活性。组织学和免疫特征反映了临床观察结果,表明类似的机制得以重现,初步数据显示所产生的肿瘤对临床治疗有反应。我们提出了一种用于研究肺腺癌的临床相关的下一代小鼠模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/2cb8655dc9e9/41598_2025_90344_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/ac882c548d18/41598_2025_90344_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/a0bf3f75c377/41598_2025_90344_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/c85b0c74fb00/41598_2025_90344_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/e06176081e6a/41598_2025_90344_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/2ac56d5d65ae/41598_2025_90344_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/2cb8655dc9e9/41598_2025_90344_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/ac882c548d18/41598_2025_90344_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/a0bf3f75c377/41598_2025_90344_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/c85b0c74fb00/41598_2025_90344_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/e06176081e6a/41598_2025_90344_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/2ac56d5d65ae/41598_2025_90344_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda3/11871348/2cb8655dc9e9/41598_2025_90344_Fig6_HTML.jpg

相似文献

1
Methodology of murine lung cancer mimics clinical lung adenocarcinoma progression and metastasis.小鼠肺癌模型的方法学模拟了临床肺腺癌的进展和转移。
Sci Rep. 2025 Feb 28;15(1):7127. doi: 10.1038/s41598-025-90344-1.
2
Metastasis suppressor 1 (MTSS1) expression is associated with reduced in-vivo metastasis and enhanced patient survival in lung adenocarcinoma.转移抑制因子 1(MTSS1)的表达与肺腺癌体内转移减少和患者生存时间延长相关。
Clin Exp Metastasis. 2018 Feb;35(1-2):15-23. doi: 10.1007/s10585-017-9869-3. Epub 2017 Dec 7.
3
Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy.使用新型鼠肺腺癌细胞系的原位模型模拟接受免疫治疗的人类非小细胞肺癌。
Cells. 2024 Jun 28;13(13):1120. doi: 10.3390/cells13131120.
4
Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion.波形蛋白通过异型肿瘤细胞-癌相关成纤维细胞相互作用在集体浸润过程中促进肺腺癌转移。
Clin Cancer Res. 2018 Jan 15;24(2):420-432. doi: 10.1158/1078-0432.CCR-17-1776. Epub 2017 Dec 5.
5
An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma.NKX2-1/ERK/WNT 反馈环路调节肺腺癌的胃组织特征和对靶向治疗的反应。
Elife. 2021 Apr 6;10:e66788. doi: 10.7554/eLife.66788.
6
RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma.RANKL 信号在肺腺癌基因工程小鼠模型中维持原发性肿瘤生长。
J Thorac Oncol. 2018 Mar;13(3):387-398. doi: 10.1016/j.jtho.2017.11.121. Epub 2017 Dec 6.
7
Destrin Contributes to Lung Adenocarcinoma Progression by Activating Wnt/β-Catenin Signaling Pathway.肌球蛋白轻链 Destrin 通过激活 Wnt/β-连环蛋白信号通路促进肺腺癌的进展。
Mol Cancer Res. 2020 Dec;18(12):1789-1802. doi: 10.1158/1541-7786.MCR-20-0187. Epub 2020 Sep 2.
8
17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression.17β-雌二醇通过 ERβ 通路上调 IL6 表达,促进肺腺癌进展。
J Exp Clin Cancer Res. 2018 Jul 3;37(1):133. doi: 10.1186/s13046-018-0804-5.
9
RBIS regulates ribosome biogenesis to affect progression in lung adenocarcinoma.RBIS调节核糖体生物合成以影响肺腺癌的进展。
J Transl Med. 2024 Dec 25;22(1):1147. doi: 10.1186/s12967-024-05886-1.
10
FHL2 expression by cancer-associated fibroblasts promotes metastasis and angiogenesis in lung adenocarcinoma.癌相关成纤维细胞表达 FHL2 促进肺腺癌的转移和血管生成。
Int J Cancer. 2025 Jan 15;156(2):431-446. doi: 10.1002/ijc.35174. Epub 2024 Sep 8.

本文引用的文献

1
Disease prognosis and therapeutic strategies in patients with advanced non-small cell lung cancer (NSCLC): a 6-year epidemiological study between 2015-2021.晚期非小细胞肺癌(NSCLC)患者的疾病预后及治疗策略:一项2015年至2021年的6年流行病学研究
Transl Cancer Res. 2024 Feb 29;13(2):762-770. doi: 10.21037/tcr-23-1816. Epub 2024 Feb 23.
2
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.国际肺癌研究协会肺癌分期项目:对即将发布的(第九版)肺癌 TNM 分类中 TNM 分期组的修订建议。
J Thorac Oncol. 2024 Jul;19(7):1007-1027. doi: 10.1016/j.jtho.2024.02.011. Epub 2024 Mar 4.
3
Lung Cancer in Never Smokers: Delving into Epidemiology, Genomic and Immune Landscape, Prognosis, Treatment, and Screening.非吸烟人群中的肺癌:深入探究流行病学、基因组和免疫景观、预后、治疗和筛查。
Lung. 2023 Dec;201(6):521-529. doi: 10.1007/s00408-023-00661-3. Epub 2023 Nov 16.
4
Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer.甲状腺转录因子-1(TTF-1)表达与免疫检查点抑制剂和细胞毒性化疗联合治疗非鳞状非小细胞肺癌的疗效
Transl Lung Cancer Res. 2023 Sep 28;12(9):1850-1861. doi: 10.21037/tlcr-23-331. Epub 2023 Sep 13.
5
Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.在五个欧洲国家,转移性非小细胞肺癌患者的治疗模式和结局:真实世界证据调查。
BMC Cancer. 2023 Jun 30;23(1):603. doi: 10.1186/s12885-023-11074-z.
6
Emerging evidence and treatment paradigm of non-small cell lung cancer.非小细胞肺癌的新证据和治疗模式。
J Hematol Oncol. 2023 Apr 17;16(1):40. doi: 10.1186/s13045-023-01436-2.
7
T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer.非小细胞肺癌患者外周血 T 淋巴细胞亚群及淋巴细胞 PD-1 表达。
Medicine (Baltimore). 2022 Oct 21;101(42):e31307. doi: 10.1097/MD.0000000000031307.
8
Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015.2015 年韩国肺癌登记协会(KALC-R):肺癌患者五年总体生存率及预后因素。
Cancer Res Treat. 2023 Jan;55(1):103-111. doi: 10.4143/crt.2022.264. Epub 2022 Jun 20.
9
Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review.代谢变化作为肺癌诊断工具的系统评价
Metabolites. 2022 Jun 14;12(6):545. doi: 10.3390/metabo12060545.
10
Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study.美国计算机断层扫描筛查与肺癌分期转移和生存的关联:准实验研究。
BMJ. 2022 Mar 30;376:e069008. doi: 10.1136/bmj-2021-069008.